AR098997A2 - Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación - Google Patents
Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipaciónInfo
- Publication number
- AR098997A2 AR098997A2 ARP140104956A ARP140104956A AR098997A2 AR 098997 A2 AR098997 A2 AR 098997A2 AR P140104956 A ARP140104956 A AR P140104956A AR P140104956 A ARP140104956 A AR P140104956A AR 098997 A2 AR098997 A2 AR 098997A2
- Authority
- AR
- Argentina
- Prior art keywords
- dosage unit
- constipation
- analogue
- analog
- suitable excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
- C07C53/23—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen containing rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Pyrane Compounds (AREA)
Abstract
Se describe una unidad de dosificación para tratar la constipación en un paciente humano. La unidad de dosificación comprende un análogo de prostaglandina halogenado y un excipiente farmacéuticamente adecuado. La unidad de dosificación alivia la constipación sin efectos colaterales sustanciales. Reivindicación 1: Una unidad de dosificación para usar con el fin de aliviar o prevenir la constipación en un paciente humano que comprende un análogo de prostaglandina (PG) representado por la fórmula (1) y/o sus tautómeros, y un excipiente farmacéuticamente adecuado, caracterizada porque la unidad de dosificación contiene dicho análogo de PG en el rango de aprox. 6 - 96 mg; en donde A¹ y A² son átomos de halógeno iguales o diferentes y B es -COOH, incluyendo sus sales, ésteres o amidas farmacéuticamente aceptables. Reivindicación 3: La unidad de dosificación de acuerdo con la reivindicación 1, caracterizada porque dicho análogo de PG está presente en el rango de aprox. 24 - 72 mg. Reivindicación 7: La unidad de dosificación de acuerdo con la reivindicación 1, caracterizada porque dicho excipiente farmacéuticamente adecuado es un ácido graso de cadena mediana.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33131601P | 2001-11-14 | 2001-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR098997A2 true AR098997A2 (es) | 2016-06-22 |
Family
ID=23293447
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104349A AR037524A1 (es) | 2001-11-14 | 2002-11-13 | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
ARP140104956A AR098997A2 (es) | 2001-11-14 | 2014-12-30 | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación |
ARP190100714A AR117404A2 (es) | 2001-11-14 | 2019-03-21 | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020104349A AR037524A1 (es) | 2001-11-14 | 2002-11-13 | Unidad de dosificacion que comprende un analogo de prostaglandina para el tratamiento de la constipacion |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190100714A AR117404A2 (es) | 2001-11-14 | 2019-03-21 | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación |
Country Status (15)
Country | Link |
---|---|
US (3) | US8097653B2 (es) |
EP (2) | EP1443938B1 (es) |
JP (2) | JP4852229B2 (es) |
AR (3) | AR037524A1 (es) |
AT (1) | ATE522218T1 (es) |
BR (1) | BR0214075A (es) |
CA (1) | CA2464420C (es) |
CY (1) | CY1115856T1 (es) |
DK (2) | DK2298314T3 (es) |
ES (2) | ES2524369T3 (es) |
HK (1) | HK1155649A1 (es) |
LU (1) | LU92826I2 (es) |
PT (2) | PT1443938E (es) |
TW (1) | TWI331920B (es) |
WO (1) | WO2003041716A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI331920B (en) * | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
US8114911B2 (en) * | 2002-10-23 | 2012-02-14 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
TWI336254B (en) * | 2002-12-27 | 2011-01-21 | Sucampo Ag | Pharmaceutical composition for treating abdominal discomfort |
DE602004030245D1 (de) * | 2003-07-03 | 2011-01-05 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | Sucampo Ag | 治療胃腸道疾病之方法及組成物 |
ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US20060281818A1 (en) | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
PT1871380E (pt) * | 2005-04-12 | 2011-11-21 | Sucampo Ag | Utilização combinada de composto de prostaglandina e inibidor de bomba de protões para o tratamento de distúrbios gastrointestinais |
PT1978944E (pt) * | 2006-01-24 | 2012-11-26 | Sucampo Ag | Formulação em cápsula de gelatina mole |
EP1984027B1 (en) * | 2006-01-24 | 2015-12-30 | R-Tech Ueno, Ltd. | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
US20090030072A1 (en) | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
NZ598783A (en) * | 2009-09-18 | 2013-07-26 | Adolor Corp | Use of opioid receptor antagonist for gastrointestinal tract disorders |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5350141A (en) | 1976-10-18 | 1978-05-08 | Ono Pharmaceut Co Ltd | Stabilization of prostaglandin and prostaglandin analogues |
GB1581886A (en) | 1977-05-26 | 1980-12-31 | May & Baker Ltd | Prostanol derivatives |
GB2210556B (en) * | 1987-10-02 | 1991-07-17 | Ueno Seiyaku Oyo Kenkyujo Kk | The use of 15-keto-16-halo-prostaglandins in cathartic compositions |
US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
JPH0681728B2 (ja) | 1987-10-02 | 1994-10-19 | 株式会社上野製薬応用研究所 | 下 剤 |
JP2579193B2 (ja) | 1988-07-19 | 1997-02-05 | 小野薬品工業株式会社 | 16,16−ジフルオロ−15−オキソ−15−デオキシpge誘導体 |
CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
CA2030346C (en) * | 1989-11-22 | 2000-04-11 | Ryuji Ueno | Treatment of cardiac dysfunction with 15-keto-prostaglandin compounds |
CA2030345C (en) * | 1989-11-22 | 1998-12-08 | Ryuji Ueno | Use of 15-keto-prostaglandin compound for improvement of encephalic function |
CA2030344C (en) * | 1989-11-22 | 2000-04-18 | Ryuji Ueno | Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds |
EP0455448B1 (en) * | 1990-05-01 | 1998-12-09 | R-Tech Ueno Ltd. | Treatment of pancreatic disease with 15-keto-prostaglandin E compounds |
CA2046069C (en) * | 1990-07-10 | 2002-04-09 | Ryuji Ueno | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
JP2938579B2 (ja) | 1990-12-15 | 1999-08-23 | 株式会社上野製薬応用研究所 | 消化管壁保護剤 |
DE69213057T2 (de) * | 1991-03-14 | 1997-01-09 | Ueno Seiyaku Oyo Kenkyujo Kk | Stimulierung von Wundheilung mit 15-Keto-prostaglandinverbindungen |
ES2118842T3 (es) * | 1992-02-04 | 1998-10-01 | Eisai Co Ltd | Derivados del acido aminobenzoico. |
CA2150287C (en) * | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
JP3183615B2 (ja) * | 1994-06-03 | 2001-07-09 | 株式会社アールテック・ウエノ | 肝・胆道系疾患処置剤 |
JP3187438B2 (ja) * | 1996-06-10 | 2001-07-11 | 株式会社アールテック・ウエノ | エンドセリン拮抗剤 |
DE19717005A1 (de) * | 1997-04-23 | 1998-10-29 | Kennametal Inc | Spannfutter für Rundlaufwerkzeuge |
CN1206997C (zh) | 1997-11-28 | 2005-06-22 | 株式会社·R-技术上野 | 内皮缩血管肽拮抗剂 |
US6492417B1 (en) | 1997-12-22 | 2002-12-10 | Alcon Manufacturing, Ltd. | 11-deoxy-16-fluoro-PGF2α analogs as FP receptor antagonists |
ES2221859T3 (es) * | 1999-10-15 | 2005-01-16 | Sucampo Ag | Composicion de compuestos biciclicos y procedimiento para su estabilizacion. |
JP4183943B2 (ja) | 2000-04-06 | 2008-11-19 | スキャンポ・アーゲー | 15−ケトプロスタグランジンを含む胆汁分泌促進剤組成物 |
US6414016B1 (en) | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
DE60225266T2 (de) | 2001-05-18 | 2009-03-19 | Sucampo Ag | Zusammensetzung mit induzierendem kathartischen effekt |
MXPA04002006A (es) | 2001-08-31 | 2004-06-07 | Sucampo Ag | Analogos de prostagladina como abridor del canal de cloruro. |
TWI331920B (en) * | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
US7732487B2 (en) | 2001-11-19 | 2010-06-08 | Sucampo Ag | Method for treating a disease or condition responsive to opening of C1C-2 channel |
TWI336254B (en) | 2002-12-27 | 2011-01-21 | Sucampo Ag | Pharmaceutical composition for treating abdominal discomfort |
-
2002
- 2002-11-13 TW TW091133227A patent/TWI331920B/zh not_active IP Right Cessation
- 2002-11-13 AR ARP020104349A patent/AR037524A1/es not_active Application Discontinuation
- 2002-11-14 US US10/293,516 patent/US8097653B2/en not_active Expired - Lifetime
- 2002-11-14 PT PT02780083T patent/PT1443938E/pt unknown
- 2002-11-14 ES ES10010211.0T patent/ES2524369T3/es not_active Expired - Lifetime
- 2002-11-14 BR BR0214075-6A patent/BR0214075A/pt not_active Application Discontinuation
- 2002-11-14 EP EP02780083A patent/EP1443938B1/en not_active Expired - Lifetime
- 2002-11-14 DK DK10010211.0T patent/DK2298314T3/en active
- 2002-11-14 DK DK02780083.8T patent/DK1443938T3/da active
- 2002-11-14 AT AT02780083T patent/ATE522218T1/de active
- 2002-11-14 CA CA2464420A patent/CA2464420C/en not_active Expired - Lifetime
- 2002-11-14 JP JP2003543603A patent/JP4852229B2/ja not_active Expired - Lifetime
- 2002-11-14 EP EP10010211.0A patent/EP2298314B1/en not_active Expired - Lifetime
- 2002-11-14 PT PT100102110T patent/PT2298314E/pt unknown
- 2002-11-14 ES ES02780083T patent/ES2368729T3/es not_active Expired - Lifetime
- 2002-11-14 WO PCT/JP2002/011862 patent/WO2003041716A1/en active Application Filing
-
2011
- 2011-05-25 JP JP2011117231A patent/JP2011201905A/ja active Pending
- 2011-09-21 HK HK11109944.5A patent/HK1155649A1/xx not_active IP Right Cessation
- 2011-12-20 US US13/330,942 patent/US8389542B2/en not_active Expired - Lifetime
-
2013
- 2013-01-30 US US13/754,138 patent/US20130143958A1/en not_active Abandoned
-
2014
- 2014-11-28 CY CY20141100997T patent/CY1115856T1/el unknown
- 2014-12-30 AR ARP140104956A patent/AR098997A2/es unknown
-
2015
- 2015-09-11 LU LU92826C patent/LU92826I2/xx unknown
-
2019
- 2019-03-21 AR ARP190100714A patent/AR117404A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20030119898A1 (en) | 2003-06-26 |
JP2005513014A (ja) | 2005-05-12 |
JP4852229B2 (ja) | 2012-01-11 |
PT2298314E (pt) | 2014-12-03 |
ES2368729T3 (es) | 2011-11-21 |
EP1443938B1 (en) | 2011-08-31 |
PT1443938E (pt) | 2011-09-27 |
CY1115856T1 (el) | 2017-01-25 |
US8097653B2 (en) | 2012-01-17 |
CA2464420A1 (en) | 2003-05-22 |
US8389542B2 (en) | 2013-03-05 |
DK2298314T3 (en) | 2014-12-01 |
AR117404A2 (es) | 2021-08-04 |
BR0214075A (pt) | 2004-09-28 |
HK1155649A1 (en) | 2012-05-25 |
US20130143958A1 (en) | 2013-06-06 |
EP2298314A1 (en) | 2011-03-23 |
TW200300091A (en) | 2003-05-16 |
DK1443938T3 (da) | 2011-09-26 |
US20120088824A1 (en) | 2012-04-12 |
EP1443938A1 (en) | 2004-08-11 |
CA2464420C (en) | 2011-12-13 |
LU92826I2 (fr) | 2015-11-24 |
ES2524369T3 (es) | 2014-12-05 |
EP2298314B1 (en) | 2014-09-03 |
AR037524A1 (es) | 2004-11-17 |
TWI331920B (en) | 2010-10-21 |
JP2011201905A (ja) | 2011-10-13 |
WO2003041716A1 (en) | 2003-05-22 |
ATE522218T1 (de) | 2011-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR098997A2 (es) | Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación | |
SE0202462D0 (sv) | Novel use | |
ES2190674T3 (es) | Uso de n-alquil derivados de cadena larga de desoxinojirimicina para la fabricacion de un medicamento para el tratamiento de enfermedades de acumulacion de glucolipidos. | |
UY26782A1 (es) | Derivados del benzotiazol | |
CO5180579A1 (es) | Composicion oral solida que comprende levidopa, carbidopa y entacapone | |
BR0210261A (pt) | Formulações farmacêuticas para a administração eficiente de apomorfina, 6ar-(-)-n-propil-norapomorfina e seus derivados e pró-drogas destes | |
MXPA03010435A (es) | Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. | |
UY26977A1 (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos | |
CO4950524A1 (es) | Inhibidores de acido nitrico sintasa | |
UA90858C2 (ru) | Композиция с контролируемым высвобождением варденафила | |
CO4960645A1 (es) | Composicion farmaceutica de drogas antiinflamatorias no- esteroides y analogos de gaba y metodos para prevenir y tratar dano gastrointestinal, enfermedad inflamatoria del intestino irritable y sindrome de privacion del alcohol | |
HUP0401192A2 (hu) | Fényérzékenyítő szer alkalmazása sebek kezelésére adható gyógyászati készítmény előállítására | |
NO20024772D0 (no) | Percyquinnin, fremgangsmåte for dets fremstilling og dets anvendelse som et legemiddel | |
HUP0402422A2 (hu) | Deuterizált szubsztituált pirazolil-benzolszulfonamid-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
NO20022442D0 (no) | Legemidler for sykdommer i forbindelse med reduksjon i benmasse | |
SE0202429D0 (sv) | Novel Compounds | |
ECSP045469A (es) | El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas | |
BR0209283A (pt) | Método para a fabricação de uma composição farmacêutica de baixa dosagem tendo distribuição e potência de droga uniforme | |
ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
HUP0201284A2 (hu) | Hatóanyagként kinazolindionszármazék kimáz inhibitort tartalmazó gyógyászati készítmények fibrózis megelőzésére vagy kezelésére | |
ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
NO975726D0 (no) | N-Hydroksyurea-derivater som anti-inflammatoriske midler | |
NO20031678L (no) | Profylaktisk og terapeutisk middel for diabetiske komplikasjoner | |
ATE393152T1 (de) | Phtalazine derivate mit angiogenesis inhibierender wirkung | |
HUP0202710A2 (hu) | Vitronektin receptor antagonisták, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |